ArticleeNeuro2026
A Multi-Network Approach Identifies Proteins Related to Dendritic Spines in Alzheimer's Disease.
Emma L Hobby, Audrey J Weber, Evan Liu, Cheyenne Hurst, Kelsey M Greathouse, Chris Gaiteri, Nicholas T Seyfried, Jeremy H Herskowitz
Abstract read
In one paragraphArticle in eNeuro, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Emma L HobbyDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Audrey J WeberDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Evan LiuDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.ORCID 0009-0002-2513-2774 Cheyenne HurstDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322.
Kelsey M GreathouseDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.
Chris GaiteriDepartment of Psychiatry, SUNY Upstate Medical University, Syracuse, New York 13210.
Nicholas T SeyfriedDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia 30322 jhersko@uab.edu nseyfri@emory.edu.
Jeremy H HerskowitzDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294 jhersko@uab.edu nseyfri@emory.edu.
Funding
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9MSynaptic Resilience to Tau in Alzheimer's DiseaseR21AG085379 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HERSKOWITZ, JEREMY H. · 2024 to 2025
$401kTau-mediated synaptic dysfunction in age-related neurodegenerative diseasesK00AG083305 · NIA · STANFORD UNIVERSITY · PI Audrey Weber · 2025 to 2026
$176kTau-mediated synaptic dysfunction in age-related neurodegenerative diseasesF99AG083305 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEBER, AUDREY · 2023 to 2024
$81kNIA NIH HHS F99 AG083305NIA NIH HHS K00 AG083305NIA NIH HHS R01 AG061800NIA NIH HHS R21 AG085379
6 · The paper itselfAbstract
Proteomic studies have generated robust assessments of protein abundance changes in Alzheimer's disease (AD); however, identifying how the protein abundance changes affect specific biological processes remains a challenge. To address these hurdles, we used a multi-network computational analysis approach that integrated dendritic spine morphometry data with mass spectrometry-based proteomics from the same individuals. The samples exhibited a range of AD neuropathology and were categorized into three groups: controls, asymptomatic AD, and AD cases. Multiplex tandem mass tag mass spectrometry proteomic data (
Indexed as
Alzheimer DiseaseDendritic SpinesPrefrontal CortexAgedAged, 80 and overFemaleHumansMaleProteomicsAlzheimer's diseasedendritic spineshuman neurosciencenetwork analysisproteomicssynapse
Identifiers
PMID41922169
PMCPMC13095402
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390